Kala initiates clinical trials for nanotechnology-based treatment platform

Kala Pharmaceuticals has initiated two clinical trials to evaluate the safety and efficacy of its proprietary mucus penetrating particle technology for managing inflammation and pain associated with cataract surgery, and for patients with dry eye disease, according to a company press release.The nanotechnology-based mucus penetrating particle (MPP) allows therapeutic agents to pass through the mucus layer of the tear film, expediting penetration into the cornea, aqueous humor and retina, according to the press release.

Full Story →